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ABSTRACT
Objective: Low-carbohydrate diets may be useful for
weight loss. Diets high in vegetable proteins and oils may
reduce the risk of coronary heart disease. The main
objective was to determine the longer term effect of a diet
that was both low-carbohydrate and plant-based on
weight loss and low-density lipoprotein cholesterol
(LDL-C).
Design, setting, participants: A parallel design study
of 39 overweight hyperlipidaemic men and
postmenopausal women conducted at a Canadian
university-affiliated hospital nutrition research centre
from April 2005 to November 2006.
Intervention: Participants were advised to consume
either a low-carbohydrate vegan diet or a high-
carbohydrate lacto-ovo vegetarian diet for 6 months after
completing 1-month metabolic (all foods provided)
versions of these diets. The prescribed macronutrient
intakes for the low-carbohydrate and high-carbohydrate
diets were: 26% and 58% of energy from carbohydrate,
31% and 16% from protein and 43% and 25% from fat,
respectively.
Primary outcome: Change in body weight.
Results: 23 participants (50% test, 68% control)
completed the 6-month ad libitum study. The
approximate 4 kg weight loss on the metabolic study was
increased to −6.9 kg on low-carbohydrate and −5.8 kg
on high-carbohydrate 6-month ad libitum treatments
(treatment difference (95% CI) −1.1 kg (−2.1 to 0.0),
p=0.047). The relative LDL-C and triglyceride reductions
were also greater on the low-carbohydrate treatment
(treatment difference (95% CI) −0.49 mmol/L (−0.70 to
−0.28), p<0.001 and −0.34 mmol/L (−0.57 to −0.11),
p=0.005, respectively), as were the total cholesterol:HDL-
C and apolipoprotein B:A1 ratios (−0.57 (−0.83, −0.32),
p<0.001 and −0.05 (−0.09, −0.02), p=0.003,
respectively).
Conclusions: A self-selected low-carbohydrate vegan
diet, containing increased protein and fat from gluten and
soy products, nuts and vegetable oils, had lipid lowering
advantages over a high-carbohydrate, low-fat weight loss
diet, thus improving heart disease risk factors.
Trial Registration: clinicaltrials.gov (http://www.
clinicaltrials.gov/), #NCT00256516.
Strengths and limitations of this study
▪ The study weaknesses include the relatively
small sample size and the high dropout rate.
Nevertheless, it is noteworthy that attrition rates
were low in the metabolic study when all food
was provided. Food availability and preparation
may therefore be important factors. For those
who did complete the study, however, there were
benefits in weight loss and low-density lipopro-
tein cholesterol (LDL-C) reduction, an additional
2% advantage in body weight reduction com-
pared with the high-carbohydrate diet and a 13%
drop in LDL-C for participants consuming a
more plant-based low-carbohydrate diet.
▪ The study’s strength is that the prescribed hypo-
caloric diet was self-selected, meaning the
results are more in line with what can be
expected under free-living conditions. The
breadth of application of the plant-based low-
carbohydrate diet, however, remains to be deter-
mined, but it may provide an option for some
individuals for whom LDL-C reduction is an
equal concern to weight loss. If low-
carbohydrate dietary options become more gen-
erally available the number of individuals who
will benefit is likely to increase.
▪ A further strength of the study is that the reduc-
tion in Framingham cardiovascular disease risk
score seen on the Eco-Atkins diet has been vali-
dated in a long-term cardiovascular disease
outcome trial using key components of the Eco-
Atkins diet (nuts and vegetable/olive oil).
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Many popular weight loss diets emphasise carbohydrate
restriction (Atkins, Eddies, South Beach, Zone). Their
success is determined by the level of compliance with
the prescribed diets.
1–6 However, a high content of
animal products, rich in saturated fat and cholesterol,
may make conventional low-carbohydrate diets less
appropriate for those with hypercholesterolaemia.
27
Even during active weight loss, these high-saturated fat
diets do not lower serum low-density lipoprotein choles-
terol (LDL-C) below baseline
27and there is concern
that if such diets continue to be eaten when weight loss
has ceased, a more atherogenic blood lipid proﬁle may
result.
8 These concerns have prompted exploration of
other weight loss strategies, but only modest reductions
in LDL-C have been observed.
9
By contrast vegan diets signiﬁcantly lower LDL-C.
10
Trials of vegan and vegetarian diets also reduce progres-
sion of coronary heart disease (CHD)
11 and improve
diabetes control.
12 Plant food components such as vege-
table proteins, vegetable oils, nuts and viscous ﬁbres,
reduce serum lipids in many studies
13–18 and may
increase ﬂow-mediated vasodilatation.
19–22 Nuts, ﬁbre
and vegetarian diets in general, all reduce CHD and dia-
betes in cohort studies.
23–28 Finally, in cohort studies,
low-carbohydrate diets, high in vegetable oils and pro-
teins as opposed to animal products, reduce CHD events
and diabetes incidence in women,
29 30 while lower red
meat intake reduces total, cardiovascular and cancer
mortality.
31 Most recently a large randomised controlled
trial conﬁrmed the effect of nuts and increased vege-
table oil (olive oil) intake in reducing cardiovascular
events in the context of a Mediterranean diet.
32
In view of the apparent success of low-carbohydrate
diets for weight loss and the demonstration that relatively
high-carbohydrate vegetarian and vegan diets, and diets
low in animal products, lower CHD risk factors,
33–36 we
designed a diet that combined both vegan and low-
carbohydrate elements to determine whether such a diet
captured both the weight loss and CHD risk reduction
advantages. We have already reported the effect of this
dietary strategy in producing a difference of 8% in
LDL-C reduction between calorie-restricted diets (60% of
estimated calorie requirements) when all food was pro-
vided.
37 We now report ﬁndings after these same partici-
pants continued on their respective diets for an
additional 6 months, under self-selected conditions, in
order to gain insights into the real-life effectiveness of
this diet. The results of the metabolic (all foods pro-
vided) study have been reported previously and had
demonstrated a CHD risk factor advantage, but with no
greater weight loss than the control diet.
37
METHODS
Participants
Forty-seven overweight participants, recruited by news-
paper advertisement and hospital clinic notices,
undertook the 1-month metabolic ﬁrst phase of the study
(ﬁgure 1) that has been previously reported.
37 At the start
of the study, participants were given the option to partici-
pate in the metabolic and ad libitum phases or only the
metabolic phase. On completion of the metabolic phase,
39 participants (19 control and 20 test participants) con-
tinued for an ad libitum 6-month study and their data
(n=39) were used in the ﬁnal analysis (table 1). The study
was conducted at a Canadian university-afﬁliated hospital
nutrition research centre from April 2005 to November
2006. All participants had high normal to raised LDL-C
levels (>3.4 mmol/L at diagnosis) and a body mass index
(BMI) >27 kg/m
2. Details of the eligibility criteria have
been previously reported.
37 After recruitment, the 11/39
participants who were taking lipid lowering medications
discontinued their medications at least 2 weeks prior to
starting and for the study duration (table 1).
Study protocol
The intervention was a randomised parallel study strati-
ﬁed by sex in which participants were randomised to
either low-carbohydrate or high-carbohydrate,
calorie-reduced diets. The ﬁrst month was the previously
reported metabolically controlled study.
37 For the follow-
ing 6 months, participants continued on the diet to
which they had been assigned as a self-selected (ad
libitum) diet. Anthropometric, blood pressure and
blood lipid measurements were repeated at monthly
intervals. Insulin and glycated haemoglobin (HbA1c)
were measured at baseline and at the start and end of
the ad libitum treatment. Percentage body fat was mea-
sured at baseline and end of the ad libitum treatment by
bioelectrical impedance (Quantum II; RJL Systems,
Clinton Township, Michigan). Seven-day diet and exer-
cise histories were recorded in the week prior to each
monthly visit. These histories were reviewed and dis-
cussed with the dietitian and appropriate dietary coun-
selling was provided to enhance adherence. The overall
feeling of satiety for the previous week was assessed at
each study visit using a 9-point bipolar semantic scale,
where −4 was extremely hungry, 0 was neutral and +4
was uncomfortably full.
34 37 No exercise advise was given
during the study, but alterations in exercise were allowed
and recorded.
Written informed consent was obtained from the parti-
cipants. The study’s clinical trial registration number was
#NCT00256516.
Diets
As with the previous metabolic study, participants were
encouraged to eat only 60% of their estimated caloric
requirements in order to continue the body weight
reduction started on their metabolic phase.
38–40 The
prescribed test diet was a low-carbohydrate vegan diet
containing 26% of calories from carbohydrate, 31% of
calories from vegetable proteins and 43% from fat (pri-
marily vegetable oils). Carbohydrate sources on the low-
carbohydrate diet featured viscous ﬁbre-containing
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(emphasising okra and eggplant) for the relatively
limited amount of carbohydrate allowed. The vegetable
proteins were prescribed as gluten (54.8% of total
protein), soy (23%), fruits and vegetables (8.7%), nuts
(7.5%), and cereals (6%). Gluten was contained in the
nut bread and wheat gluten (also called ‘seitan’)p r o -
ducts. Soy protein was present in the form of burgers,
deli slices, breakfast links, veggie bacon, tofu and soy
milks. Nuts included almonds, cashews, hazelnuts, maca-
damia, pecans and pistachios. The fat sources were nuts
(43.6% of total fat), vegetable oils (24.4%), soy products
(18.5%), avocado (7.1%), cereals (2.7%), fruits and
vegetables (2.3%), and seitan products (1.4%).
Participants were able to purchase at the research centre
the ‘no’ starch high protein nut bread and three of the
seitan (wheat gluten) products used in the study which
were not available in Canada. The control, high-
carbohydrate lacto-ovo vegetarian diet (58% carbohy-
drate, 16% protein and 25% fat) emphasised whole
wheat cereals and cereal ﬁbre, as well as low-fat or skim
milk dairy products and liquid egg substitute to reduce
saturated fat and cholesterol intakes. These diets have
been published previously.
37 Participants were given a
Figure 1 Patient flow diagram. *Chose not to participate (29): busy lifestyle (13); not interested (6); study too demanding (3);
currently on another diet (2); no compensation (2); work-related (2); dislike prepackaged foods (1). **Other reasons (44): unable
to contact (19); unable to come to clinic (13); away (5); throat surgery (1); bowel resection (1); high potassium and BP (1); high
potassium (1); raised liver function tests (1); not interested (1); medical insurance issue (1).
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and amounts prescribed during the metabolic phase.
These menu plans served as a reference during the ad
libitum phase. Furthermore, participants were given an
exchange list of the items prescribed on the menu plan.
The goal was to enhance adherence.
Self-taring electronic scales (My Weigh Scales,
Vancouver, BC or Tanita Corporation, Arlington
Heights, Illinois) were provided to all participants and
they were instructed to weigh all food items while
recording the 7-day food diary in the week prior to
monthly clinic visits. Adherence to the three principal
cholesterol-lowering components (vegetable proteins
(soy and gluten), nuts and viscous ﬁbres) of the low-
carbohydrate diet was assessed from the completed
monthly 7-day food records. The amount of each com-
ponent provided during the metabolic phase remained
the same as that prescribed during the ad libitum phase.
Neither the dietitians nor participants could be
blinded, but equal emphasis was placed on the potential
importance for health of both diets. The analytical tech-
nicians were blinded to diet allocation, as was the statisti-
cian, up to analysis of the primary outcome. Participants
were offered no ﬁnancial compensation for participation
in the study.
Analyses
The analytical techniques have been reported previ-
ously.
37 Serum was analysed in the J. Alick Little Lipid
Research Laboratory. LDL-C (in mmol/L) was calcu-
lated by the method of Friedewald et al using all data
including the two participants who had baseline and
during study triglyceride values above 4.5 mmol/L
(3 values on low-carbohydrate diet and 2 on high-
carbohydrate diet, maximum triglyceride <6.5 mmol/L;
exclusion of these two individuals did not alter the ﬁnd-
ings). The methods for analysing apolipoproteins A1
(ApoA1) and B (ApoB), high sensitivity C reactive
protein (hs-CRP), blood glucose, insulin, HbA1c and
homoeostasis model assessment—insulin resistance
model (HOMA-IR) have been described previously.
37
Exercise data were calculated as metabolic equivalents
(METs).
41 The absolute 10-year CHD risk score was cal-
culated using the Framingham risk equation.
42
Diets were assessed for macronutrients, fatty acids,
cholesterol and ﬁbre using a computer programme
based on the US Department of Agriculture (USDA)
database
43 and developed in our laboratory to allow the
addition of the macronutrient content of study foods
obtained from food labels or directly from food manu-
facturers. The nutritional proﬁles of the diets were cal-
culated from the 7-day food records completed once a
month throughout the study and mean intakes are
presented.
Adherence to the three principal cholesterol-lowering
components (vegetable proteins (soy and gluten), nuts
and viscous ﬁbres) of the low-carbohydrate diet was esti-
mated from the 7-day food records. Each component
was assessed as contributing 1/3 or 33.3% to the LDL-C
reduction. When the amount consumed was equivalent
to the amount prescribed a 33.3% compliance would be
recorded for that component. The sum of the three
components if consumed as prescribed would equal
100% adherence.
Table 1 Baseline characteristics for those who started the 6-month self-selected diets (n=39)
High carbohydrate (n=19) Low carbohydrate (n=20)
Age (years) 55.3±1.8 57.6±1.4
Males/females 6/13 9/11
Body weight (kg) 85.4 (79.3 to 91.6) 83.7 (78.5 to 89.0)
Body mass index (kg/m
2) 31.1 (29.9 to 32.4) 31.1 (29.8 to 32.4)
Blood pressure (mm Hg)
Systolic 122 (116 to 128) 128 (123 to 132)
Diastolic 75 (72 to 79) 77 (74 to 80)
Cholesterol (mmol/L)
Total 6.75 (6.28 to 7.21) 6.76 (6.21 to 7.31)
LDL-C 4.40 (3.99 to 4.82) 4.53 (4.14 to 4.93)
HDL-C 1.36 (1.22 to 1.50) 1.21 (1.06 to 1.36)
Triglycerides (mmol/L) 2.16 (1.62 to 2.70) 2.23 (1.65 to 2.80)
Ratios
TC:HDL-C 5.17 (4.54 to 5.80) 5.81 (5.20 to 6.41)
LDL-C:HDL-C 3.35 (2.95 to 3.75) 3.89 (3.49 to 4.29)
Medications
Lipid lowering (prior to start of study) 4 7
Blood pressure 3 6
Diabetes 0 0
Thyroid 2 1
Values represent mean±SEM or 95% CIs.
No significant differences between treatments at baseline assessed by two sample t test (two-tailed).
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.
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Results are expressed as means±SEM or 95% CIs. Time
zero was used as the baseline and refers to the premeta-
bolic study baseline.
37 Treatment differences in physical
and biochemical measures were assessed using all avail-
able data from the 39 participants and a repeated mea-
sures mixed model accounting for time of assessment
(SAS V.9.2)
44 in tables 2 and 3 and the Results section.
The response variable was change from baseline, with
diet and week as ﬁxed effects and subject ID nested in
diet. There was no adjustment for baseline. Any partici-
pant who started the ad libitum treatment was included
in the analysis (N=39). The completer analysis included
the 23 participants who completed the study (ﬁgure 1).
Multiple imputation (taking the mean of ﬁve sets of
randomly imputed values) was used to present baseline
and treatment values in tables 2 and 3 and ﬁgures 2 and
3 by generating data for those who dropped out or had
missing values.
44
RESULTS
Compliance with the major dietary components (vege-
table proteins (soy and gluten), nuts and viscous ﬁbres)
was 33.6% or one-third of that prescribed during the
metabolic phase (table 2). Saturated fat intakes were
similar on both treatments whereas intake of monoun-
saturated fats (MUFAs), vegetable proteins and soy
protein were signiﬁcantly higher on the low-
carbohydrate diet (table 2). Available carbohydrate
intake was signiﬁcantly lower on the low-carbohydrate
diet (table 2).
The attrition rate was 50% (10/20) on the low-
carbohydrate and 32% (6/19) on the high-carbohydrate
(ﬁgure 1) diets, this equates to a total attrition rate of
41% (16/39). The number of participants who did not
complete the study (including dropouts and withdra-
wals) did not differ between treatments. Three partici-
pants were withdrawn by the study physician due to
failure to attain LDL-C targets on the low-carbohydrate
diet (mean LDL-C=5.24 mmol/L) and one participant
on the high-carbohydrate diet (LDL-C=7.78 mmol/L).
Participants on the low-carbohydrate diet tended to have
larger reductions in body weight over time (ﬁgure 2).
The weight loss from baseline to the end of the 6-month
ad libitum treatment was −6.9 kg (95% CI −7.7 to −6.1)
on the low-carbohydrate and −5.8 kg (95% CI −6.6 to
−5.1) on the control diet with a signiﬁcant difference
between groups (treatment difference (95% CI) −1.1 kg
(−2.1 to 0.0); p=0.047; table 3). The ﬁnal reduction in
BMI was also greater on the low-carbohydrate versus
high-carbohydrate diet (treatment difference (95% CI)
−0.4 kg/m
2 (−0.8 to 0.0); p=0.039; table 3). Among the
completers, there were numerically larger differences
between treatments for both body weight and BMI
(treatment difference (95% CI) −1.8 kg (−3.0 to −0.6);
p=0.004 and −0.7 kg/m
2 (−1.1 to −0.2); p=0.004,
respectively).
There was a relative increase in recorded exercise by
the high-carbohydrate diet participants, whereas there
was no relative change in the low-carbohydrate partici-
pants (treatment difference (95% CI) −9.3 (−16.4 to
−2.2) METs; p=0.012), but this was not reﬂected in a
greater weight loss (table 3). There were no treatment
differences in percent body fat, waist circumference or
satiety (table 3).
Lipids
At the end of the study, the reduction on the low-
carbohydrate versus high-carbohydrate diet was greater
for LDL-C (treatment difference (95% CI) −0.49 mmol/L
(−0.70 to −0.28); p<0.001, for total cholesterol (TC)
−0.62 mmol/L (−0.86 to −0.37); p<0.001, for TC:high-
density lipoprotein carbohydrate (HDL-C) −0.57 (−0.83
to −0.32); p<0.001, for LDL-C:HDL-C −0.42 (−0.60 to
−0.24); p<0.001 and for triglycerides (−0.34 mmol/L
(−0.57 to −0.11); p=0.005). No treatment difference was
seen in HDL-C (table 3). A similar pattern was observed
in the completers. The treatment difference was numer-
ically larger for LDL-C (−0.60 mmol/L (−0.84 to
−0.36); p<0.0001), TC (−0.73 mmol/L (−1.00 to −0.45);
p<0.0001), TC:HDL-C (−0.68 (−0.97 to −0.39);
p<0.0001) and LDL-C:HDL-C (−0.53 (−0.73 to −0.32);
p<0.0001). Values for LDL-C and the TC:HDL-C ratio
were consistently lower in participants on the low-
carbohydrate diet throughout the study while HDL-C
values were not different from baseline (ﬁgure 3A–C).
Apolipoproteins
ApoB and the ApoB:ApoA1 ratio were reduced more on
the low-carbohydrate versus the high-carbohydrate diet
at the end of the study (treatment different (95% CI)
−0.11 g/L (−0.16 to −0.06); p<0.001 and −0.05 (−0.09
to −0.02); p=0.003, respectively; table 3). No signiﬁcant
difference between the diets was observed for ApoA1
concentrations. The pattern of change in the apolipo-
proteins in the completers reﬂected the changes seen in
the whole group. Figure 3D,F show that the low-
carbohydrate diet resulted in lower ApoB and ApoB:
ApoA1 ratios relative to baseline over the course of the
study.
CRP, HbA1c, blood glucose, serum insulin, insulin
resistance and blood pressure
Both treatments reduced hs-CRP with no difference
between treatments (table 3). HbA1c, fasting blood
glucose, insulin and insulin resistance (calculated using
the HOMA model) fell similarly on both treatments
during the course of the study (table 3). Systolic and dia-
stolic blood pressure decreased similarly with no treat-
ment differences (table 3). The completers also failed to
show a difference between treatments.
Calculated CHD risk
The low-carbohydrate diet signiﬁcantly reduced the cal-
culated 10-year CHD risk relative to the high-
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Open AccessTable 2 Nutritional profiles on the high-carbohydrate and low-carbohydrate diets (n=39)
High carbohydrate Low carbohydrate Between-treatment
difference† p Value‡ Week 0* Ad libitum* Week 0* Ad Libitum*
Calories (kcal) 1598 (1421 to 1775) 1347 (1140 to 1553) 1840 (1550 to 2130) 1388 (1234 to 1541) −248 (−391 to −106) 0.001
Percentage of total calories
Available carbohydrate 46.3 (42.2 to 50.4) 53.9 (50.2 to 57.5) 43.8 (40.2 to 47.4) 39.6 (35.7 to 43.6) −10.5 (−13.6 to −7.5) <0.001
Protein 20.6 (18.7 to 22.5) 18.4 (17.4 to 19.5) 20.1 (18.0 to 22.2) 22.7 (20.1 to 25.4) 5.9 (4.3 to 7.5) <0.001
Vegetable protein 5.6 (5.0 to 6.1) 6.7 (6.1 to 7.3) 5.7 (5.3 to 6.1) 15.0 (11.7 to 18.2) 8.2 (6.5 to 9.9) <0.001
Soy protein 0 (0 to 0) 0.2 (0.1 to 0.2) 0 (0 to 0) 4.7 (2.7 to 6.8) 3.6 (2.9 to 4.4) <0.001
Fat 30.8 (27.3 to 34.4) 27.5 (24.6 to 30.4) 34.4 (31.4 to 37.5) 36.0 (31.5 to 40.5) 5.2 (2.6 to 7.7) <0.001
Saturated 10.8 (9.1 to 12.6) 7.6 (6.2 to 8.9) 11.8 (10.3 to 13.3) 7.5 (6.6 to 8.4) −0.4 (−1.4 to 0.6) 0.401
Monounsaturated 12.3 (10.7 to 13.8) 10.4 (9.3 to 11.6) 13.0 (11.9 to 14.2) 14.8 (13.1 to 16.6) 4.6 (3.1 to 6.1) <0.001
Polyunsaturated§ 5.2 (4.6 to 5.8) 6.3 (5.4 to 7.2) 6.6 (5.5 to 7.8) 8.4 (7.5 to 9.4) 0.4 (−0.5 to 1.4) 0.350
Alcohol 2.2 (0.3 to 4.2) 1.9 (0.7 to 3.2) 1.6 (0.0 to 3.3) 1.1 (0.1 to 2.1) −0.5 (−1.3 to 0.2) 0.160
Dietary fibre (g/1000 kcal) 10.9 (9.2 to 12.5) 18.2 (15.2 to 21.1) 12.1 (9.9 to 14.4) 21.3 (18.8 to 23.8) 1.5 (−0.5 to 3.5) 0.127
Dietary cholesterol (mg/1000 kcal) 149 (129 to 169) 87 (61 to 113) 157 (136 to 177) 117 (44 to 189) 11 (−22 to 23) 0.954
Adherence with ‘Eco-Atkins’ components¶
Viscous fibre (of 33.3%) ––– 14.0 (9.4 to 18.6) ––
Vegetable protein (soy and gluten; of
33.3%)
––– 14.7 (10.3 to 19.1) ––
Nuts (of 33.3%) ––– 6.3 (3.3 to 9.3) ––
Total adherence (of 100%) ––– 33.6 (22.1 to 45.2) ––
Values represent mean±95% CIs.
*Values represent multiple imputation (taking the mean of 5 sets of randomly imputed values) to generate data for those who dropped out or had missing values.
†Between-treatment difference, change from baseline between the two diets using all available data.
‡p-Values assessed using all available data and a repeated measures mixed model accounting for time of assessment. The response variable was change from baseline, with diet and week as
fixed effects and subject ID nested in diet. There was no adjustment for baseline.
§Significantly different between-treatments at baseline assessed by two sample t test (two tailed), p=0.025.
¶Adherence represents the mean percentage intake of the prescribed intake of the three cholesterol-lowering components (viscous fibre, vegetable protein (soy and gluten), nuts) by expressing
the recorded intake for each component as 33.3%. The sum of the three components if consumed as prescribed would equal 100% adherence.
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sTable 3 Effect of high-carbohydrate and low-carbohydrate diets on body weight, blood lipids, apolipoproteins and 10-year CHD risk (n=39)
High carbohydrate Low carbohydrate Between-treatment
difference† p Value‡ Week 0* Ad libitum* Week 0* Ad libitum*
Body weight (kg) 85.4 (79.3 to 91.6) 80.4 (74.2 to 86.6) 83.7 (78.5 to 89.0) 76.9 (71.9 to 81.9) −1.1 (−2.1 to 0.0) 0.047
BMI 31.1 (29.9 to 32.4) 29.2 (27.9 to 30.5) 31.1 (29.8 to 32.4) 28.7 (27.3 to 30.1) −0.4 (−0.8 to 0.0) 0.039
Body fat (%) 38.9 (34.0 to 43.8) 35.0 (30.7 to 39.2) 35.6 (30.1 to 41.1) 31.4 (26.1 to 36.6) −1.7 (−4.0 to 0.7) 0.161
Waist circumference (cm) 102.8 (99.4 to 106.2) 97.4 (93.1 to 101.6) 99.8 (96.1 to 103.5) 93.7 (89.8 to 97.7) 0.1 (−1.1 to 1.3) 0.861
Fasting glucose 5.2 (4.9 to 5.4) 4.6 (4.5 to 4.7) 5.2 (5.0 to 5.4) 4.6 (4.4 to 4.9) 0.1 (−0.1 to 0.2) 0.447
HbA1c (%) 5.2 (5.0 to 5.4) 5.2 (5.0 to 5.3) 5.3 (5.0 to 5.5) 5.2 (5.0 to 5.4) 0.0 (−0.2 to 0.1) 0.852
Fasting insulin 50.0 (38.3 to 61.7) 36.4 (27.5 to 45.4) 47.3 (36.9 to 57.6) 33.3 (22.8 to 43.9) −0.6 (−9.1 to 8.0) 0.898
HOMA-IR 1.65 (1.17 to 2.13) 1.11 (0.81 to 1.41) 1.53 (1.19 to 1.88) 0.99 (0.68 to 1.30) 0.01 (−0.30 to 0.33) 0.937
Satiety (−4 to 4) 1.0 (0.7 to 1.4) 0.9 (0.7 to 1.2) 1.2 (0.8 to 1.7) 1.1 (0.8 to 1.4) −0.1 (−0.4 to 0.2) 0.440
Exercise, METs 17.4 (12.4 to 22.4) 25.8 (21.1 to 30.6) 24.0 (12.9 to 35.0) 23.9 (15.3 to 32.6) −9.3 (-16.4 to −2–2) 0.012
Cholesterol (mmol/L§)
Total 6.75 (6.28 to 7.21) 6.49 (5.97 to 7.02) 6.76 (6.21 to 7.31) 6.10 (5.67 to 6.53) −0.62 (−0.86 to −0.37) <0.001
LDL-C 4.40 (3.99 to 4.82) 4.40 (3.91 to 4.90) 4.53 (4.14 to 4.93) 4.06 (3.71 to 4.42) −0.49 (−0.70 to −0.28) <0.001
HDL-C 1.36 (1.22 to 1.50) 1.35 (1.22 to 1.48) 1.21 (1.06 to 1.36) 1.25 (1.10 to 1.39) 0.03 (−0.02 to 0.07) 0.245
Triglycerides 2.16 (1.62 to 2.70) 1.71 (1.35 to 2.07) 2.23 (1.65 to 2.80) 1.50 (1.22 to 1.77) −0.34 (−0.57 to −0.11) 0.005
Ratios
TC:HDL-C 5.17 (4.54 to 5.80) 4.92 (4.49 to 5.34) 5.81 (5.20 to 6.41) 5.13 (4.65 to 5.62) −0.57 (−0.83 to −0.32) <0.001
LDL-C:HDL-C 3.35 (2.95 to 3.75) 3.34 (3.00 to 3.68) 3.89 (3.49 to 4.29) 3.48 (3.06 to 3.90) −0.42 (−0.60 to −0.24) <0.002
Apolipoproteins (g/L)¶
ApoA1 1.69 (1.60 to 1.78) 1.69 (1.60 to 1.77) 1.57 (1.45 to 1.69) 1.57 (1.46 to 1.67) −0.02 (−0.06 to 0.02) 0.316
ApoB 1.38 (1.26 to 1.50) 1.23 (1.13 to 1.33) 1.42 (1.30 to 1.54) 1.20 (1.10 to 1.31) −0.11 (−0.16 to −0.06) <0.001
ApoB: ApoA1 0.83 (0.74 to 0.91) 0.74 (0.68 to 0.80) 0.92 (0.84 to 0.99) 0.78 (0.70 to 0.86) −0.05 (−0.09 to −0.02) 0.003
Hs-CRP (mg/dL) 2.1 (1.0 to 3.3) 1.9 (1.3 to 2.4) 3.0 (1.5 to 4.5) 2.6 (1.0 to 4.1) −0.4 (−0.9 to 0.1) 0.082
Blood pressure (mm Hg)
Systolic 122 (116 to 128) 118 (114 to 122) 128 (123 to 132) 123 (119 to 128) −2( −5 to 2) 0.356
Diastolic 75 (72 to 79) 74 (71 to 77) 77 (74 to 80) 76 (71 to 80) −1( −3 to 1) 0.288
10-year CHD risk (%)** 8 (6 to 9) 7 (6 to 9) 12 (9 to 14) 9 (7 to 11) −2( −2 to -1) <0.001
Values represent mean±95% CIs.
*Values represent multiple imputation (taking the mean of 5 sets of randomly imputed values) to generate data for those who dropped out or had missing values.
†Between-treatment difference, change from baseline between the two diets using all available data.
‡p-values assessed using all available data and a repeated measures mixed model accounting for time of assessment. The response variable was change from baseline, with diet and week as
fixed effects and subject ID nested in diet. There was no adjustment for baseline.
§To convert total cholesterol, LDL-C, and HDL-C to mg/dL, divide by 0.0259; to convert triglycerides to mg/dL, divide by 0.0113.
¶To convert apolipoprotein A1 and B to mg/dL, multiply by 100.
**Significantly different between-treatments at baseline assessed by two sample t test (two tailed), p=0.007.
BMI, body mass index; CHD, coronary heart disease; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homoeostasis model assessment—insulin
resistance model; Hs-CRP, high-sensitivity C reactive protein; LDL-C, low-density lipoprotein cholesterol; MET, metabolic equivalents; TC, total cholesterol.
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scarbohydrate diet (2% (−2% to −1%); p<0.001; table
3). A reduced CHD risk on the low-carbohydrate diet
was also observed in the completers (2% (−3% to
−1%); p<0.001).
Adverse events
No serious adverse events or events that involved hospi-
talisation occurred during the study.
DISCUSSION
The present study demonstrated that consumption of a
low-carbohydrate vegan diet resulted in a modestly
greater body weight reduction compared with a high-
carbohydrate diet (7% vs 6% reductions, respectively)
over a 6-month ad libitum period. These reductions
were similar to those reported for low-carbohydrate
‘Atkins-like’ diets.
1259However, by comparison with
the high-carbohydrate diet, consumption of the low-
carbohydrate diet containing vegetable proteins and oils
was also associated with signiﬁcantly reduced concentra-
tions of LDL-C. This LDL-C reduction has not been
reported for other low-carbohydrate diet studies in
which a large part of the protein and fat originated
from animal sources and in which no signiﬁcant LDL-C
reductions were seen.
1–57The sustained reduction in
LDL-C, associated with a small incremental weight loss
on the 6-month self-selected diet, is a potentially import-
ant attribute of the diet in reducing long-term CHD
risk.
45 46 Furthermore, as seen in the present study, a
low-carbohydrate diet, in which vegetable fat and
protein options were encouraged, demonstrated a larger
reduction in the TC:HDL-C ratio than that reported at
6 months in weight loss studies employing either a
Mediterranean or a high-carbohydrate diet.
9
The majority of studies undertaken to date have been
6 months to 1 year in duration
1–54 7with recent studies
of up to 2 years.
17The high dropout rate in the present
6-month study did not prevent identiﬁcation of signiﬁ-
cant LDL-C and body weight differences in the
intent-to-treat analysis (using all available data).
However, the completer data demonstrated an even
larger treatment difference in LDL-C favouring the low-
carbohydrate treatment. Those on the low-carbohydrate
diet showed overall adherence to the major dietary com-
ponents (vegetable proteins (soy and gluten), nuts and
viscous ﬁbres) at 33.6% of that provided during the
metabolic phase.
37 This adherence is similar to the
43.3% seen with the dietary portfolio in the comparison
of the metabolic 1 month
34 and the ad libitum 6-month
studies.
48 In this study, the LDL-C reduction on the low-
carbohydrate metabolic month was also greater than
that on the ad libitum 6 months, although the treatment
differences were similar.
34
The effect of low-carbohydrate diets on CHD events
has not been assessed in randomised controlled trials.
Nevertheless, low-carbohydrate diets high in vegetable
proteins and oils have been associated with a 30%
reduced CHD risk and an 18% reduced incidence of
diabetes in cohort studies.
29 30 The median interquartile
difference in these studies between the 1st and 10th
decile for vegetable protein and MUFA intakes, as a
marker of increased vegetable oil consumption, was
1.4% and 9.3% expressed as a percentage of total
calorie intake.
29 These ﬁgures compare with an 8.2%
and a 4.6% relative increase in vegetable protein and oil
consumption from baseline on the Eco-Atkins diet com-
pared with the control diet. The increases in MUFA
were therefore seen in both studies. Recently a Spanish
Mediterranean diet emphasising increased nut or olive
oil consumption, and so increasing MUFA intake by 2–
3%, has been shown to signiﬁcantly reduce cardiovascu-
lar events also by approximately 30%.
32 These data
provide consistent support for the view that the
Eco-Atkins approach would reduce CHD risk in the long
term.
The present diet, while lowering LDL-C by 9%, did
not result in any signiﬁcant depression of HDL-C.
Lowering LDL-C while maintaining HDL-C would be
expected to reduce CHD risk.
45 46 Similarly, reductions
in ApoB and the ApoB:ApoA1 ratio were also observed
in the present study. These ﬁndings further support the
potential CHD beneﬁt that this weight loss diet may
have.
49–51 It has also been claimed that apolipoproteins
may be stronger predictors of CHD events than conven-
tional lipid variables.
52–54
In contrast to the metabolic study, the reductions in
systolic and diastolic blood pressure were not signiﬁcant
between the low-carbohydrate and high-carbohydrate
Figure 2 Weight loss during the study on both diets. Weight
loss during the study on both diets. Values represent mean
±SEM of the change from baseline during the metabolic and
ad libitum phases, using multiple imputation (taking the mean
of 5 sets of randomly imputed values) to generate data for
those who dropped out or had missing values on the ad
libitum phase. The change in weight during the ad libitum
phase was significantly reduced (P=0.047) on the low versus
the high carbohydrate diet using all available data in the
repeated measures mixed model analysis. Cross hatched bar
represents the metabolic phase.
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Open Accessdiets. Similarly, hs-CRP was unchanged between treat-
ments, however, the level was signiﬁcantly reduced with
the low-carbohydrate diet compared with baseline.
Studies have shown that hs-CRP tended to be lowest in
the diets containing the highest proportion of carbohy-
drate.
4 Low-glycaemic index and low-glycaemic load
diets have also been associated with lower hs-CRP con-
centrations.
55 56 These advantages of the higher carbo-
hydrate diet may have reduced any hs-CRP difference
between the two diets in the present study.
Soy-containing foods as well as nuts have cholesterol-
lowering effects
14 16 17 57 58 and may explain the reduc-
tion in LDL-C. Viscous ﬁbre in low starch vegetables and
β-glucan in oats and barley may also have contributed to
the overall cholesterol-lowering effect of the diet.
81 34 5
Furthermore, nuts and high ﬁbre food consumption
have been associated with lower body weight.
59
The study weaknesses include the relatively small
sample size and the high dropout rate. Nevertheless, it is
noteworthy that attrition rates were low in the metabolic
study when all food was provided.
37 Food availability and
preparation may therefore be important factors. Future
studies will need to focus on strategies to increase and
maintain adherence, especially to the cholesterol-
lowering components, which all bear US Food and Drug
Administration (FDA) health claims for cardiovascular
disease risk reduction. Furthermore, collaboration with
food industry may be helpful in addressing concerns of
availability, variety and ease of preparation. In retrospect,
a simpliﬁed one page eating plan for breakfast, lunch
and dinner with a number of options and amounts for
each meal, as we have used in our dietary portfolio
studies, might also be helpful.
48 For those who did com-
plete the study, however, there were beneﬁts in weight
loss and LDL-C reduction, an additional 2% advantage
in body weight reduction compared with the high-
carbohydrate diet and a 13% drop in LDL-C for partici-
pants consuming a more plant-based low-carbohydrate
diet. Unfortunately it was not possible to predict who
would complete the diet based on prestudy data or
changes observed during the metabolic phase.
The study’s strength is that the prescribed hypocaloric
diet was self-selected, meaning the results are more in line
with what can be expected under free-living conditions. The
breadth of application of the plant-based low-carbohydrate
diet, however, remains to be determined, but it may provide
Figure 3 Change in (A) LDL-C, (B) HDL-C, (C) TC:HDL-C, (D) Apolipoprotein B (apoB), (E) Apolipoprotein A1 (apoA1), (F)
ApoB:ApoA1 ratio between the two treatments during the metabolic and ad libitum phases. Values represent mean ±SEM of the
change from baseline using multiple imputation (taking the mean of 5 sets of randomly imputed values) to generate data for
those who dropped out or had missing values for the ad libitum phase. Significant treatment differences were seen for LDL-C
(p<0.001), apo B (p<0.001) and the ratios TC:HDL-C (p<0.001) and apoB:apoA1 (p=0.003). using all available data in the
repeated measures mixed model analysis during the ad libitum phase. Cross hatched bar represents the metabolic phase.
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Open Accessan option for some individuals for whom LDL-C reduction
is an equal concern to weight loss. If low-carbohydrate
dietary options become more generally available the
number of individuals who will beneﬁti sl i k e l yt oi n c r e a s e .
We conclude that a weight loss diet which reduced
carbohydrate in exchange for increased intakes of vege-
table sources of protein, such as gluten, soy and nuts,
together with vegetable oils offers an opportunity to
improve both LDL-C and body weight, both being risk
factors for CHD. Further trials are warranted to evaluate
low-carbohydrate diets, including more plant-based low-
carbohydrate diets, on CHD risk factors and ultimately
on CHD.
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